Evidence map›Paper›PMID 39850647›Full record

ArticleHemaSphere2025

Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma.

Xiang Zhou, Annika Hofmann, Benedict Engel, Cornelia Vogt, Silvia Nerreter, Yoko Tamamushi, Friederike Schmitt, Maria Leberzammer, Emilia Stanojkovska, Marietta Truger and 12 more

Abstract read
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review.Blood and lymphatic cancer : targets and therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Xiang ZhouDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.ORCID 0000-0001-5772-7700
Annika HofmannDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Benedict EngelDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Cornelia VogtDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Silvia NerreterDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Yoko TamamushiDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Friederike SchmittDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Maria LeberzammerDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Emilia StanojkovskaDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Marietta TrugerMunich Leukemia Laboratory (MLL) Munich Germany.
Xianghui XiaoDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Christine RiedhammerDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Maximilian J SteinhardtDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Mara JohnMildred Scheel Early Career Center Würzburg Germany.
Julia MersiDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Seungbin HanDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Umair MunawarDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Johannes M WaldschmidtDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Claudia HaferlachMunich Leukemia Laboratory (MLL) Munich Germany.
Hermann EinseleDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
Leo RascheDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.
K Martin KortümDepartment of Internal Medicine II University Hospital of Würzburg Würzburg Germany.ORCID https://orcid.org/0000-0002-7011-0286

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The definition of high-risk (HR) multiple myeloma (MM) is still a matter of debate. We prospectively evaluated the HR detection using FISH in combination with SKY92 gene expression profiling in 258 MM patients (newly diagnosed [ND] MM:

Identifiers

PMID39850647
PMCPMC11754766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.